SCHEMBL1597034

SCHEMBL1597034

CC(=O)N(C)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL3155059 0.97 CHRM1 (0.41)
Alcohol SCHEMBL11264817 0.92 TDP1 (0.42)
SCHEMBL31047724 0.90 MVD (0.42)
SCHEMBL29702696 0.90 MVD (0.42)
SCHEMBL29333999 0.90 MVD (0.42)
SCHEMBL1634020 0.79
SCHEMBL112280 0.79
SCHEMBL4586640 0.78 TDP1 (0.38)
SCHEMBL22540356 0.78
SCHEMBL9216352 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651876-A1 TARGETED THERANOSTIC AGENTS FOR IMAGING AND TREATING CANCER The Board of Regents of the University of Texas System (US) 2025-11-26 EP claimed
CN-120115713-A Preparation method of smooth and compact silver-coated copper powder 东方电气集团科学技术研究院有限公司 2025-06-10 CN claimed
EP-4547258-A1 NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY Transcode Therapeutics, Inc. (US) 2025-05-07 EP claimed
WO-2024155993-A1 TARGETED THERANOSTIC AGENTS FOR IMAGING AND TREATING CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-07-25 WO claimed
WO-2024006362-A1 NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY TRANSCODE THERAPEUTICS, INC. (US) 2024-01-04 WO claimed
US-20230398243-A1 THERAPEUTIC, RADIOLABELED NANOPARTICLES AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-12-14 US claimed
EP-4240429-A1 THERAPEUTIC, RADIOLABELED NANOPARTICLES AND METHODS OF USE THEREOF The General Hospital Corporation (US) 2023-09-13 EP claimed
CN-113686834-B Preparation method of SERS substrate integrating pyroelectric effect and plasmon resonance effect 暨南大学 2023-04-18 CN claimed
WO-2022098768-A1 THERAPEUTIC, RADIOLABELED NANOPARTICLES AND METHODS OF USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2022-05-12 WO claimed
CN-113686834-A Preparation method of SERS substrate integrating pyroelectric effect and plasmon resonance effect 暨南大学 2021-11-23 CN claimed
US-7723333-B2 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators ASTRAZENECA AB (SE) 2010-05-25 US claimed
EP-2076525-A2 COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE Wisconsin Alumni Research Foundation (US) 2009-07-08 EP claimed
US-20090005353-A1 Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators ASTRAZENECA AB (SE) 2009-01-01 US claimed
WO-2008067039-A9 COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE WISCONSIN ALUMNI RES FOUND (US) 2008-10-16 WO claimed
US-20080171787-A1 COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-07-17 US claimed
WO-2008067039-A2 COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-06-05 WO claimed
EP-1838687-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2007-10-03 EP claimed
WO-2006073366-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2006-07-13 WO claimed
US-20030132416-A1 Stripping solution SHIPLEY COMPANY, L.L.C. 2003-07-17 US claimed
US-4010149-A PEPTIDE SANKYO COMPANY LIMITED (JA) 1977-03-01 US claimed